Product Specification
| Alternative Name: | Phosphatase of regenerating liver 3, Protein tyrosine phosphatase type IVA 3 |
| |
| MW: | ~19.5kDa |
| |
| Source: | Produced in E. coli. The catalytic domain of PRL-3 (aa 2-173) is fused at the N-terminus to a His-tag. |
| |
| EC: | 3.1.3.48 |
| |
| UniProt ID: | O75365 |
| |
| Concentration: | 0.05μg/μl |
| |
| Formulation: | Liquid. In 40mM TRIS-HCl, pH 8.0, containing 110mM sodium chloride, 2.2mM potassium chloride, 20% glycerol, and 3mM dithiothreitol. |
| |
| Purity: | ≥90% (SDS-PAGE) |
| |
| Specific Activity: | 0.774U/μg. One unit will hydrolyze 1pmol para-nitrophenyl phosphate (PNPP) per minute at 37°C. Assay buffer: 50mM TRIS, pH 7.4, containing 150mM sodium chloride, 5mM dithiothreitol and 12.5mM PNPP. |
| |
| Application Notes: | Useful for studies of enzyme kinetics and regulation, dephosphorylation of target substrates, and inhibitor screening. |
| |
| Shipping: | Shipped on Dry Ice |
| |
| Long Term Storage: | -80°C |
| |
| Use/Stability: | Dilution of the enzyme followed by refreezing may lead to loss of activity. |
| |
| Scientific Background: | PRL phosphatases comprise a class of small oncogenic phosphatases that are prenylated at their carboxyl-termini. PRL-3 is overexpressed in colon tumors metastasizing to the liver, but not in normal colorectal epithelium. Metastatic lesions have also shown gene amplification of the PRL-3 gene. PRL-3-blocking antibodies reduce metastatic tumor formation by cells overexpressing PRL-3. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
General Literature References
Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice: K. Guo, et al.; Cancer Biol. Ther.
7, 750 (2008),
Abstract;
Full Text
A phosphatase associated with metastasis of colorectal cancer: S. Saha, et al.; Science
294, 1343 (2001),
Abstract;
